Clinical Trials Update: June 7, 2005

Healthy Women Studies Peritoneal Cancer Pemphigus Vulgaris (PV)

(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:

Healthy Women Studies

The Columbus Center for Women's Health Research is conducting a clinical research study of an investigational medication for the prevention of pregnancy in women of childbearing potential. You may be eligible to participate in this national research study if you are between the ages of 18 and 40, and are currently taking an oral contraceptive and have had three regular menstrual cycles. Research site located in Columbus, OH.

More Information

Please see http://www.centerwatch.com/patient/studies/cat438.html.

-----

Peritoneal Cancer

The purpose of this study is to determine the effectiveness of the investigational drug BAY 43-9006 in treating epithelial ovarian cancer or primary peritoneal cancer. This investigational agent blocks an important mechanism that controls the growth of cancer cells. Participants must have recurrent or persistent epithelial ovarian or primary peritoneal carcinoma, measurable disease and be free of infection. Research site located in Elgin, Ill.

More Information

Please see http://www.centerwatch.com/patient/studies/cat553.html.

-----

Pemphigus Vulgaris (PV)

This study will assess the efficacy and safety of CellCept in patients with pemphigus vulgaris receiving prednisone or other corticosteroids. During the study, patients will undergo gradual dose reduction of corticosteroids if they respond to treatment. Participants must be 18 to 70 years of age, and have a diagnosis of mild-to-moderate pemphigus vulgaris within the past 24 months requiring high-dose corticosteroids. Research sites located throughout Germany and Great Britain.

More Information

Please see http://www.centerwatch.com/patient/studies/cat617.html.

-----

Copyright 2005 CenterWatch. All rights reserved.

Related Stories

No stories found.
logo
www.healthday.com